IGC Pharma (NYSEAM:IGC) Q2 2026 Earnings Call November 17, 2025 11:00 AM ET Company ParticipantsRam Mukunda - CEORosalyn Christian - Head of Investor RelationsConference Call ParticipantsEdward Wu - Equity Research AnalystJames Malloy - Managing Director, and Biotechnology, and Specialty Pharmaceuticals Equity Research AnalystAdam Snyder - Senior Equity AnalystOperatorLadies and gentlemen, greetings, and welcome to the IGC Pharma mid-year fiscal 2026 shareholder update call. At this time, all participants a ...

IGC Pharma (NYSEAM:IGC) Q2 2026 Earnings Call November 17, 2025 11:00 AM ET Company ParticipantsRam Mukunda - CEORosalyn Christian - Head of Investor RelationsOperatorLadies and gentlemen, greetings, and welcome to the IGC Pharma mid-year fiscal 2026 shareholder update call. At this time, all participants are in a listen-only mode. Please note this conference is being recorded. Following management's remarks, the call line will be opened for questions. It is now my pleasure to introduce your host, Rosalyn C ...

Financial Data and Key Metrics Changes - The company reported a non-cash profit of approximately $1.1 million from the divestiture of a non-core manufacturing facility, which was sold for about $2.7 million [20][21] - The company has renewed its $12 million line of credit and is focused on minimizing dilution while maintaining a clean capital table [17] Business Line Data and Key Metrics Changes - IGC 81 is currently in a phase two trial, with over 50% enrollment completed, and the company is optimistic about finishing the trial in the first half of next year [4][9] - The CALMA trial, which focuses on agitation in Alzheimer's patients, has expanded to multiple sites in the U.S. and Canada, with a significant increase in patient recruitment [10][28] Market Data and Key Metrics Changes - The company is addressing a significant unmet need in the Alzheimer's market, with over 55 million diagnosed patients and 400 million at risk due to Alzheimer's pathology [5][16] - The company is developing an AI-based diagnostic platform, MINT-AD, aimed at early detection and prediction of cognitive decline in Alzheimer's patients [13][14] Company Strategy and Development Direction - The company is focused on advancing its multi-asset pipeline, particularly IGC 81, which is seen as a near-term opportunity to drive shareholder value [6][12] - The strategic divestiture of the Vancouver manufacturing facility allows the company to redirect resources and management attention towards accelerating the CALMA trial and advancing other small molecule assets [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in completing the CALMA trial and achieving significant milestones in the upcoming year, which they believe will enhance shareholder value [18][31] - The company is not expecting any impact from recent legislation affecting the hemp industry on its pharmaceutical development and FDA approval processes [24][25] Other Important Information - The company is in the semi-final round for a $1 million prize aimed at advancing Alzheimer's research through AI, with a presentation scheduled for December 5 [29][31] - The company has received recognition for its work, including awards from the National Institute on Aging, highlighting its commitment to Alzheimer's research [29] Q&A Session Summary Question: Will there be another interim data analysis before the trial completion? - Management indicated that they do not expect another readout and are focused on completing the trial and the final readout [20] Question: Why was the Vancouver manufacturing facility divested? - The divestiture was strategic to eliminate $600,000 in annual operating expenses and redirect resources to accelerate the CALMA trial [20][21] Question: Are there plans for Canadian approval alongside FDA approval? - Yes, the company plans to seek approval in both the U.S. and Canada as the trial is being conducted in both regions [23] Question: Will the recent government funding bill impact the phase two trial? - Management clarified that the bill targets the consumer hemp market and does not affect the regulatory pathway for prescription drugs like IGC 81 [24][25] Question: How is enrollment going for the CALMA trial? - Enrollment has significantly increased, with a rise from signing up four patients a month to 14, aided by online advertising and geotargeting [28]

Core Insights - The third quarter of 2025 showed a 7% decline in revenue, amounting to DKK 347 million, with adjusted EBITDA of DKK 24 million, reflecting a margin of 6.9% [1][7][12] - The company maintains its full-year outlook, citing signs of improved customer activity and a solid pipeline [1][9] Q3 2025 Highlights - Revenue from Dynamics 365 decreased by 12% year-over-year, while M3 revenue increased by 8% [4] - Total service revenue declined by 7% to DKK 329 million, with total net revenue also down by 7% [4][8] - The EBITDA margin for Q3 2025 was 4.5%, down from 7.9% in Q3 2024, indicating a decrease in operational efficiency [7] Year-to-Date (YTD) 2025 Highlights - YTD revenue decreased by 4% to DKK 1.191 billion, with an adjusted EBITDA of DKK 89 million, slightly up from DKK 87 million in YTD 2024 [7] - The efficiency ratio for YTD 2025 was 61%, compared to 62% in the previous year [7] Market Performance - The company experienced varied performance across regions, with significant declines in Norway (17%) and Denmark (13%), while the US saw a growth of 28% [8] - The overall service revenue split indicates a challenging market environment, particularly in the Nordics [6][8] Future Outlook - The company expects revenue to align with 2024 levels, targeting approximately DKK 1.7 billion, with an EBITDA margin forecasted between 7-9% [12]

Group 1 - The total money supply in Hong Kong, measured by M2 and M3, decreased by 1.9% in August, but increased by 4.0% compared to the same month last year [1] - The seasonally adjusted M1 money supply fell by 2.9% in August, while it rose by 16.1% year-on-year, reflecting investment-related activities [1] - Total deposits in recognized institutions increased by 0.9% in August, with Hong Kong dollar deposits declining by 2.1% and foreign currency deposits rising by 3.3%, indicating corporate fund flows [1] Group 2 - The total amount of loans and advances decreased by 0.4% in August, but increased by 1.0% year-to-date as of the end of August [2] - Loans used in Hong Kong and those used outside of Hong Kong fell by 0.1% and 1.3% respectively in August [2] - The loan-to-deposit ratio for Hong Kong dollars increased from 73.1% at the end of July to 74.6% at the end of August due to a larger decline in Hong Kong dollar deposits compared to loans [2]

Core Viewpoint - The smartphone industry is facing challenges due to market saturation and lack of innovation, but the emergence of AI presents new opportunities for manufacturers like Meizu to target underserved segments of the market [1][2]. Group 1: Company Strategy - Meizu, now under Xingji Meizu after being acquired by Geely, aims to leverage AI to differentiate itself in a competitive market dominated by larger players like Huawei and Xiaomi [2][3]. - The company has adopted an "All in AI" strategy, focusing on integrating AI capabilities into its mid-range and entry-level smartphones, particularly the newly launched Meizu Note 16 series [1][2]. - Meizu's approach emphasizes "AI equality," aiming to provide AI functionalities to users who have been overlooked by other manufacturers, such as blue-collar workers and older adults [1][3]. Group 2: AI Implementation - The AI features in Meizu's smartphones are designed to address practical needs, allowing users to perform tasks like ordering food or booking rides with simple voice commands [1][3]. - Meizu's Flyme AIOS 2 operating system has been upgraded to enhance task understanding and execution, enabling users to issue complex commands with minimal input [3][5]. - The company plans to utilize both local processing and cloud computing to deliver AI functionalities, although the reliance on cloud services raises concerns about cost [5][6]. Group 3: Cost Challenges - The implementation of AI in mid-range devices is heavily dependent on cloud services, which incurs significant costs, estimated at 1.2 to 1.5 cents per call to the cloud model [5][6]. - Meizu acknowledges the high costs associated with AI model training and cloud usage but believes that these costs will decrease over time as technology advances [5][6]. - The company is focused on improving user interaction experiences, particularly through voice commands, to enhance the value proposition of its AI offerings [5]. Group 4: Competitive Landscape - Other manufacturers, such as OPPO, Vivo, and Honor, are also integrating AI capabilities into their mid-range devices, which could challenge Meizu's strategy of focusing on cloud-based AI solutions [6]. - The potential for widespread adoption of AI in lower-priced smartphones suggests that Meizu's current path may face increased competition as the market evolves [6].

Summary of Edwards Lifesciences (EW) Conference Call Company Overview - **Company**: Edwards Lifesciences (EW) - **Industry**: Medical Devices, specifically focusing on heart valve technologies and related innovations Key Points and Arguments Financial Performance and Guidance - **Q4 and Q1 Performance**: Strong performance in Q4 and Q1, maintaining guidance for 2025 with revenue growth expected between 8% to 10% and EPS between $2.4 to $2.5 [5][11] - **Long-term Growth Commitment**: Aiming for double-digit growth (10%+) starting in 2026, with EPS growth expected to outpace revenue growth [11][12] Product Innovations and Market Opportunities - **TAVR (Transcatheter Aortic Valve Replacement)**: Early approval for TAVR expected to drive multi-year growth opportunities; significant patient benefits anticipated from new technologies [6][30] - **EVOQUE Technology**: CE Mark approval for the first transcatheter mitral replacement in Europe; strong data presented on Resilia technology [6][7] - **Emerging Opportunities**: Acquisition of Jesse Medical and ongoing pivotal studies in heart failure technologies [7][8] Supply Chain and Tariff Impact - **Supply Chain Resilience**: Global supply chain footprint is robust, with minimal impact from tariffs; the company is well-protected against tariff fluctuations [13][14][16] - **Tariff Impact on EPS**: Estimated impact of tariffs on EPS is around $0.05 per share, with more significant effects expected in 2026 [15] NCD (National Coverage Determination) and Regulatory Environment - **NCD Reopening for TAVR**: Anticipation that CMS will reopen the NCD for TAVR based on solid data and the procedure's established status as standard care [25][26] - **Guideline Changes**: Ongoing policy and guideline changes expected to further support TAVR growth [30][39] Training and Market Penetration - **Training for EVOQUE Centers**: Significant demand for EVOQUE centers; training processes in place to ensure rapid onboarding of new centers [51][55] - **Market Awareness**: Efforts underway to educate physicians on new data and implications for practice, aiming to drive referrals to interventionalists [34][40] Acquisitions and Future Growth - **Strategic Acquisitions**: Recent acquisitions (Endotronic, InnoValve, Jesse Medical) are expected to enhance the company's portfolio and address various heart conditions [61][63] - **Long-term Vision**: Commitment to long-term growth in structural heart disease, with expectations for significant contributions from new technologies [50][62] Additional Important Insights - **Leadership and Execution**: Strong leadership team noted for effective management of financial performance and strategic priorities [20][22] - **Patient-Centric Approach**: Emphasis on patient care and outcomes as a core value of the company, beyond just business metrics [37][59] This summary encapsulates the key discussions and insights from the Edwards Lifesciences conference call, highlighting the company's financial outlook, product innovations, market strategies, and commitment to patient care.

Core Insights - Columbus demonstrated solid operational performance in Q1 2025, with improved earnings and a robust business strategy despite a slight revenue decline of 2% [1][2] Financial Performance - Total net revenue for Q1 2025 was DKK 434 million, down from DKK 444 million in Q1 2024, reflecting a 2% decrease [5] - EBITDA increased by 32% to DKK 46 million compared to the adjusted EBITDA in Q1 2024, resulting in an EBITDA margin of 10.7%, up from 7.9% in Q1 2024 [5] - The efficiency rate remained consistent at 62% for both Q1 2025 and Q1 2024 [5] Service Revenue Breakdown - Service revenue by business lines showed a decline in Dynamics 365 (-2%), M3 (-9%), Digital Commerce (-11%), and Other Local Business (-21%), while Data & AI saw a significant increase of 28% [3] - Total sales of services decreased by 3% year-over-year, while total sales of products increased by 29% [3] Market Unit Performance - Revenue from various market units showed declines in Sweden (-11%), Denmark (-6%), Norway (-18%), and Other (-15%), while the UK and US markets experienced growth of 17% and 50%, respectively [4] Outlook - The company maintains its full-year guidance for 2025 based on the financial performance in Q1 2025 and the current order book and pipeline forecast [7]